Never stop innovation
  • 50 %
    The ratio of R&D staff
  • 20 %
    the ratio of R&D spending
  • 41
    申请专利数
  • As a national high tech enterprise, FAPON is dedicated to strengthening research and development and acting closely with the market, and this constant innovation has made FAPON the benchmark in the IVD raw materials industry.
    推荐文章 / Recommend Article
    • Eukaryotic recombinant expression platform
    • Chemiluminescence platform
    • 3
    • 2
    • Eukaryotic recombinant expression platform
    What paints a rosy future for FAPON is the recombinant antibody/antigen production of expressing plasmid transfection directional domestication CHO cells and screening of stable high yield cell lines, which is based on the mammalian cell expression system. This production of antibodies can bring genetic optimization, higher expression, larger volume, higher stability, smaller batch variances, and higher antibody purity. Some products are superior to those produced in the traditional way in terms of activity, specificity and thermal stability. This technology platform not only integrates the advantages of traditional technology, but also can avoid the disadvantages, which makes the monoclonal antibody production automated, efficient and economical.  At the same time, by gene recombination technology, antibodies produced can meet the needs of different subject research and markets. This indicates the direction of future development of monoclonal antibodies.
    • 化学发光平台
    FAPON attaches great importance to independent research and development, and follows international trends closely. The innovative chemiluminescence platform will be launched at MEDICA 2017, which will be taken place at Dusseldorf, Germany during Nov. 13-16,2017. Welcome to visit us and explore more at Fapon’s booth: Hall 3,A81.
    Patent
    • 专利1
    • 2
    • 3
    • 5
    • 4
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 16
    • 18
    • 19